⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 3, 2024Open Access

Supplementary Figure S4 from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids

Kanve N. Suvilesh Yariswamy Manjunath Yulia I. Nussbaum Mohamed Gadelkarim Murugesan Raju Akhil Srivastava Guangfu Li Wesley C. Warren Chi‐Ren Shyu Feng Gao Matthew A. Ciorba Jonathan B. Mitchem Satyanarayana Rachagani Jussuf T. Kaifi

View Full Paper

Ask AI

Bookmark

Share

Abstract

Supplementary Figure S4. Cellular heterogeneity comparison between matched patient-derived tumor organoids (PDTOs) and patient primary tumors (PT).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Suvilesh et al. (2024) studied this question.

synapsesocial.com/papers/68e598dfb6db643587533900 https://doi.org/10.1158/1078-0432.26926666

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S4 from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids2024
2Supplementary Figure S6 from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids2024
3Supplementary Figure S6 from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids2024
4Supplementary Figure S5 from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids2024
5Supplementary Figure S5 from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids2024

More related papers

Supplementary Figure S3 from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids2024
Supplementary Figure S3 from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids2024
Supplementary Figure S2 from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids2024